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ABSTRACT 
These British Association for Psychopharmacology guidelines cover the range and aims of treatment for 
anxiety disorders. They are based explicitly on the available evidence and are presented as 
recommendations to aid clinical decision-making in primary and secondary medical care. They may also 
serve as a source of information for patients and their carers. The recommendations are presented together 
with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety 
disorders reviewed the main subject areas and considered the strength of evidence and its clinical 
implications. The guidelines were constructed after extensive feedback from participants and interested 
parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the 
diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse 
prevention and approaches for patients who do not respond to first-line treatments.  
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INTRODUCTION 
The British Association for Psychopharmacology (BAP) aims to advance education and research in the 
science of psychopharmacology, by arranging scientific meetings, fostering research and teaching, 
encouraging publication of research results and providing guidance and information to the public and 
professions on matters relevant to psychopharmacology (www.bap.org.uk). As an important part of this 
process the BAP has published a series of evidence-based guidelines for the use of drugs in psychiatric 
disorders with the emphasis on producing comprehensive but concise and useable guidelines based on a 
review of the evidence (Anderson et al., 2000; Goodwin et al., 2003; Lingford-Hughes et al., 2004).  
 
Anxiety symptoms and disorders are common in community settings, and in primary and secondary 
medical care. The personal and societal burden associated with anxiety disorders is considerable, but many 
people who might benefit from treatment are not recognised or treated. Likely factors include the range of 
anxiety disorders, their comorbidity with other disorders (particularly depression), lack of awareness of 
anxiety disorders by sufferers and practitioners, poor confidence by many practitioners in their treatment, 
and the relative lack of research. Conversely, some patients receive unnecessary or inappropriate treatment. 
Hence there is much room for improvement in the recognition and management of patients with anxiety 
disorders; we hope these guidelines will contribute to this process.  
 
METHODOLOGY 
Guidelines are systematically derived statements that aim to inform individual patient and clinician 
decisions. Recommendations regarding treatment can be graded according to the strength of scientific 
evidence, and if possible are derived from systematic reviews and randomized controlled trials (RCTs). The 
principal recommendations apply to the management of average patients, and therefore can be expected to 
apply much of the time: for this reason, we use expressions such as ‘clinicians should consider…’ in the 
summary tables. We accept that there are many patients and many clinical decision points where 
unthinking adherence to treatment recommendations may be potentially harmful. In situations where the 
evidence is weaker we have noted management options, being aware that implementation will depend upon 
clinician experience, patient clinical features and preference, and local circumstance (Haynes et al., 2002). 
Some of our recommendations may be regarded as standards of clinical care that are driven by ethical 
considerations or custom and practice: these standards are intended to be applied rigidly.  
 
Guideline process 
These guidelines are the final result of a British Association for Psychopharmacology (BAP) consensus 
meeting on 20-21 May 2004 which included experts in the field and representatives of user groups (all 
those who attended are listed in the acknowledgments). Brief presentations were made on key areas, with 
greatest emphasis on systematic reviews and RCTs. This was followed by discussion of important issues, in 
order to identify areas of consensus or uncertainty.  A literature review was then performed to validate the 
consensus points. This was circulated to the participants and other interested parties, together with a 
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summary of the recommendations and their strength, based on the level of evidence. Wherever possible 
feedback was incorporated into the final version of the guidelines. Given the range and depth of the subject 
area it was not possible for all participants in the wider group to achieve full consensus on all points. 
 
Literature Search 
All the consensus points and the guideline recommendations can be linked to relevant evidence through the 
literature review. It was not possible to perform a systematic review of all possible data from primary 
sources. Existing systematic reviews and RCTS were identified from MEDLINE and EMBASE searches 
and from the Cochrane Database, as well as from recent previous guidelines (Ballenger et al., 1998 [a], 
1998 [b]; Ballenger et al., 2001; Bandelow et al., 2002; Allgulander et al., 2003; Greist et al., 2003; 
Pollack et al., 2003; Stein et al., 2004; Van Ameringen et al., 2003; Ballenger et al., 2004) through cross-
referencing, and by discussion with experts in the field.  
 
STRENGTH OF EVIDENCE AND RECOMMENDATIONS FOR GUIDELINES 
As in previous BAP guidelines, the categories of evidence for causal relationships and grading of 
recommendations are taken from the methodology of the North of England Evidence-Based Guideline 
Development Project undertaken by the Centre for Health Services Research, University of Newcastle upon 
Tyne and Centre for Health Economics, University of York (Shekelle et al., 1999).  
 
Evidence categories  
Evidence categories are adapted from the US Agency for Health Care Policy and Research Classification 
(US Department of Health and Human Services, 1992).  Six categories are available, when considering 
causal relationships and treatments, and we have proposed four categories for observational findings and 
associations (See Table 1). 
 
INSERT TABLE ONE ABOUT HERE 
 
Strength of recommendations 
Recommendations are graded as shown in Table 1. Weaker levels of recommendations (B, C or D) do not 
necessarily imply a reduced level of clinical importance. As in previous recommendations (Goodwin et  
al.,  2003) we have included a category S (representing a standard of care), denoting a recommendation that 
incorporates an important clinical consensus on good practice rather than factual evidence.  
 
RANGE AND AIM OF THE GUIDELINES 
We anticipate that the content of the guidelines will be relevant to all doctors treating patients with anxiety 
disorders, in primary and secondary medical care settings. Each of the principal disorders  - generalised 
anxiety disorder (GAD), panic disorder (PD), social phobia (also known as social anxiety disorder, SAD), 
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post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD) - is considered in turn, 
following key steps in management (acute treatment; continuation treatment; prevention of relapse; 
combination with psychological approaches; treatment resistance).  
 
We anticipate that the guidelines will prove most useful in informing treatment decisions in primary and 
secondary care regarding pharmacological management in patients aged between 18-65 years. The type and 
prevalence of anxiety disorders changes during childhood and adolescence (Costello et al., 2003) and the 
mean age of onset of adult patients with anxiety disorders varies between diagnoses. Nevertheless many 
adult patients describe an onset of symptoms in childhood or adolescence, and certain recommendations 
(for example those pertaining to obsessive-compulsive disorder) will be potentially applicable to adolescent 
patients. Similarly, recommendations that are applicable to adult patients do not necessarily become invalid 
once they exceed their sixty-fifth birthday.  
 
We have considered those guidelines developed by the National Institute for Clinical Excellence for 
generalised anxiety disorder, panic disorder, post-traumatic stress disorder, and obsessive-compulsive 
disorder (NICE, www.nice.org.uk), and those from other organisations, such as the recent statements from 
the World Federation of Societies of Biological Psychiatry (Bandelow et al., 2002) and the World Council 
on Anxiety (Allgulander et al., 2003; Greist et al., 2003; Pollack et al., 2003; Stein et al., 2003; Van 
Ameringen et al., 2003).  
 
There is often a tension between existing established clinical practice and the possible implications of new 
research for changing practice. Existing practice may be accepted on the basis of prolonged clinical 
experience and by extension of a related proven indication; new treatments may have superior efficacy to 
placebo in methodologically robust RCTs, but lack comparator data against current treatment. We have 
highlighted where this tension is greatest, but do not wish to impose specific treatment recommendations 
that may prove premature. 
 
EPIDEMIOLOGY OF ANXIETY SYMPTOMS AND DISORDERS 
Anxiety symptoms are common in the general population and in primary and secondary medical care. 
Symptoms may be mild, transient and without associated impairment in social and occupational function, 
but many patients are troubled by severe and persistent symptoms that cause significant personal distress, 
impair function and reduce quality of life. To meet the diagnosis of an anxiety disorder, patients have to 
experience a certain number of symptoms for more than a minimum specified period, the symptoms 
causing significant distress, with an associated impairment in everyday function. Most research has used 
the diagnostic categories for anxiety disorders in the Fourth Edition of the Diagnostic and Statistical 
Manual (DSM-IV) (American Psychiatric Association, 1994) which are broadly similar to those in the 
Tenth Edition of the International Classification of Diseases (ICD-10) (World Health Organisation, 1992); 
we give simplified versions of the disorders in Table 2.  
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 INSERT TABLE TWO ABOUT HERE 
Epidemiological studies in the general population aged 18-65 years (I) indicate that when taken together 
anxiety disorders have a 12-month period prevalence of approximately 15%, and a lifetime prevalence of 
approximately 21% (Wittchen and Jacobi, 2005). Individual disorders are less frequent, with estimated 12-
month prevalence rates ranging between 0.3% (OCD) and 7.6% (specific phobia), and estimated lifetime 
prevalence rates between 0.8% (OCD) and 13.2% (specific phobia) (Table 3). The age and sex distribution 
of individual disorders varies: for example, specific phobias are markedly more common in women than 
men across all age bands, whereas panic disorder is almost as frequent in men and women aged 51-65 
years. Due to this variation within individual anxiety disorders, the pattern for all disorders taken together 
is fairly constant with an overall female: male ratio of approximately 2:1 across the age range. Studies in 
primary care suggest approximately 50% significantly improve over 6-16 months (II) (Ronalds et al., 1997; 
Ormel et al., 1991, 1993) but complete recovery is relative rare. Severity, duration of illness and ongoing 
social adversity were associated with lack of improvement (II) (Ronalds et al., 1997). Long-term follow-up 
of participants in 8 studies of cognitive behavior therapy (CBT) for anxiety disorders found that 52% had at 
least one diagnosis, with significant levels of comorbidity and health scores comparable to the lowest 10% 
of the population (Durham et al, 2005). A US longitudinal study indicates that the likelihood of recovery 
from GAD is significantly less than that of recovering from major depression (II) (Yonkers et al., 2000).  
 
INSERT TABLES THREE AND FOUR ABOUT HERE 
 
Co-existing depressive symptoms are common, particularly in patients with severe anxiety, and many 
patients simultaneously fulfil diagnostic criteria for anxiety and depressive disorders, this pattern often 
being named ‘co-morbidity’. Cross-sectional studies in European community and clinical settings (Fehm et 
al, 2005; Goodwin et al, 2005; Lieb et al, 2005) and in UK primary medical care (Nease and Aikens, 2003) 
reveal a significant correlation between measures of anxiety and depressive symptom severity.  
Epidemiological studies indicate that approximately 62% of subjects with an anxiety disorder fulfil 
diagnostic criteria for another psychiatric disorder, most commonly depression, which is present in around 
33.5% of subjects with any disorder being considerably more common in subjects with GAD and social 
phobia (I) (Wittchen and Jacobi, 2005). In practice the presence of marked co-existing depressive 
symptoms is an important consideration in treatment decisions in primary and secondary medical care. 
Where the anxiety symptoms are present within the context of a depressive disorder, drug treatment of the 
depression is effective in improving anxiety (Anderson et al., 2000) .  Where depression follows or is 
comorbid with an anxiety disorder it is generally indicative of greater severity and associated with poorer 
prognosis (II) (Albus and Scheibe, 1993; Brown et al., 1995; Cowley et al., 1996; Shalev et al., 1998; 
Martinsen et al., 1998; Rief et al., 2000; Erwin et al., 2002). Clinical practice has been to direct treatment 
towards the depressive disorder in the first instance, choosing treatments that also have action against the 
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symptoms of the anxiety disorder; this has been shown to improve outcome in OCD, with better response 
to sertraline than desipramine (Ib) (Hoehn-Saric et al., 2000). 
 
DETECTION AND DIAGNOSIS OF ANXIETY DISORDERS 
In drawing up the guidelines we are aware that there are often practical and conceptual difficulties in 
delineating specific anxiety disorders, ranging from overlap with milder degrees of depression (‘mixed 
anxiety and depression’) to co-morbidity between anxiety disorders. The diagnosis of some anxiety 
disorders has also been criticised, with comments relating to potential legal implications (e.g. PTSD) or so-
called medicalisation of normal variation (e.g. social phobia). Nevertheless the current diagnostic 
classification provides a useful clinical delineation of distressing and debilitating symptom clusters that, 
crucially for an evidence-based approach, has been used for patient selection in treatment trials and 
therefore allows assessment of clinical benefit.  
 
From relatively sparse evidence, the detection of a mental health problem in patients with anxiety disorders 
in primary care varies between studies, but is probably similar to that for depression with values ranging 
from 56 % to 92%, the differing disorders varying in recognition rates (I) (Tiemens et al., 1996; Wittchen 
et al., 2003; Ormel et al., 1990; Ronalds et al., 1997). Co-morbidity of anxiety with depression improves 
the detection of mental health problems (Sartorius et al., 1996; Wittchen et al., 2002). However correct 
identification of which anxiety disorder is present and subsequent active treatment may be less good for 
anxiety disorders than for depression (Wittchen et al., 2002).  
 
Screening questions and self-report questionnaires are fairly sensitive but not very specific, making the 
value of routine screening for anxiety disorders questionable (Goldberg and Bridges, 1987, Dowell et al., 
1990, Lewis and Wessely 1990; Parkerson & Broadhead, 1997; Bjelland et al., 2002; Wittchen and Boyer, 
1998). The Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983) is a widely used brief self-
report scale with anxiety and depression sub-scales (7 items each); it has sensitivity and specificity of about 
0.8 for both sub-scales using a cut-off of 8 or above (Bjelland et al., 2002) making it reasonable for use in 
high risk populations. The World Health Organisation has recently published guidance on the identification 
and management of mental health problems in primary health care (World Health Organisation, 2004). A 
suggested simple algorithm for initial delineation of anxiety disorder subtypes is suggested in Figure 1.  
 
INSERT FIGURE ONE ABOUT HERE 
 
GENERAL ISSUES IN THE TREATMENT OF ANXIETY DISORDERS 
 
When to treat 
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Anxiety symptoms exist on a continuum and many people with milder degrees of anxiety, particularly of 
recent onset and associated with stressful life events but with little disability will experience an 
improvement without specific intervention (II) (Mann et al., 1981). In milder forms of depression the 
benefit of antidepressant treatment over placebo is difficult to demonstrate (Ia) (Khan et al., 2005) and the 
same is likely to be true of anxiety disorders. Randomised controlled trials across a range of anxiety 
disorders often demonstrate a high placebo response (e.g. Oosterbaan et al., 2001; Huppert et al., 2004) 
indicating that non-specific effects can play a large part in improvement. However the chronic nature and 
associated disability of many disorders means that most patients who fulfil diagnostic criteria for an anxiety 
disorder are likely to benefit from some form of treatment.  
 
This need for treatment is determined by the severity and persistence of symptoms, the presence of 
comorbid mental disorder or physical illness, the level of disability and impact on social functioning, 
concomitant medication, and a history of good response to, or poor tolerability of, previous treatment 
approaches. Because randomised controlled trials are generally performed in rather restricted patient groups 
with little comorbidity or other features commonly seen in conventional clinical samples, study findings 
may not necessarily simplify treatment decisions in primary or secondary care. Choice of treatment is 
affected by the patient characteristics (such as previous response or contraindications), the evidence base 
supporting its use, patient and physician preference, and the local availability of that proposed intervention 
(IV) (Haynes et al., 2002). Although there is considerable overlap between effective therapies for the 
different anxiety disorders there are also differences (discussed in the individual sections) and separate 
evidence bases for treating each disorder (Ib). For this reason identifying individual disorders is helpful.  
 
 
The principal options include a range of pharmacological treatments, psychological therapies based on 
exposure and cognitive methods, and self-help strategies. 
 
Pharmacological treatments 
Many patients are cautious about starting psychotropic drug treatment, fearing problems such as unwanted 
sedation or the development of physical or psychological dependence, and doctors should discuss the 
relative benefits and risks of proposed interventions before initiating a treatment prescription. It should be 
emphasised that response is not immediate; that transient worsening of symptoms can sometimes occur; 
that prolonged courses are needed to maintain an initial treatment response and minimise the risk of 
relapse; and that antidepressants (when used) are not “addictive” (Nutt, 2003).  
 
The selection of a particular drug class (and of a specific drug within that class) should be determined 
principally by the evidence base supporting its use, and also by whether the patient has previous experience 
of treatment with that compound. The absence of a licensed indication does not necessarily mean an 
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absence of evidence for the proposed treatment intervention. Conversely it should not be assumed that all 
drugs within a class are likely to be efficacious in the treatment of a particular anxiety disorder, when one 
member of that class has proven efficacy. The presence of significant coexisting depressive symptoms 
should guide treatment choice towards prescription of antidepressant drugs rather than benzodiazepines. 
The major adverse effects and problems associated with prescription of psychotropic drugs mentioned in 
the sections on treatment of individual anxiety disorders are summarised in Table 5.  
 
INSERT TABLE FIVE ABOUT HERE 
 
Selective serotonin reuptake inhibitors and venlafaxine 
Selective serotonin reuptake inhibitors (SSRIs) have broad spectrum anxiolytic efficacy and are generally 
well tolerated, and for this reason generally represent the first-line pharmacological treatment approach in 
anxiety disorders. However SSRIs have potentially troublesome adverse effects, including initial increased 
nervousness, insomnia, and nausea (Ib) (Baldwin and Birtwistle, 1998) and sexual dysfunction (Ib) 
(Baldwin, 2004). When stopped abruptly, most SSRIs can produce a discontinuation syndrome 
characterised by dizziness, insomnia and flu-like symptoms (Ib) (Schatzberg et al., 1997). The serotonin-
noradrenaline reuptake inhibitor (SNRI) venlafaxine is also associated with discontinuation symptoms after 
abrupt withdrawal (Ib) (Silverstone and Ravindran, 1999). 
 
The United Kingdom Committee on Safety of Medicines (CSM) recommends that patients are monitored 
frequently and carefully when starting or increasing the dosage of SSRI and other antidepressant treatments 
(CSM, 2004), and recent guidance from the National Institute of Clinical Excellence (NICE, 2004) on the 
treatment of panic disorder and generalised anxiety disorder recommends that patients are reviewed at 
fortnightly intervals in the first six weeks of treatment. Due to concerns about its potential safety in 
overdose, the CSM currently recommends that venlafaxine treatment should only be initiated by specialist 
mental health practitioners, requires pre-treatment ECG and blood pressure measurement, and is avoided in 
patients with cardiac disease, electrolyte imbalances or hypertension (IV) (CSM, 2004). Current advice 
regarding the relative safety of antidepressants after overdose has however been questioned (Nutt, 2005a). 
 
Tricyclic antidepressants and monoamine oxidase inhibitors 
Certain tricyclic antidepressants (TCAs) are efficacious in some anxiety disorders, but are associated with a 
greater burden of adverse effects than either SSRIs or venlafaxine, and for this reason TCAs should only be 
used after non-response to or poor tolerance of SSRI or SNRI treatment. TCAs should be avoided in  
patients considered at risk of suicide, due to their potential cardiac and CNS toxicity after overdose (Nutt, 
2005a). Stopping TCAs abruptly can also cause a discontinuation syndrome, and pharmacokinetic 
interactions can limit their use in patients taking concomitant medication. The irreversible monoamine 
oxidase inhibitor (MAOI) phenelzine has proven efficacy in panic disorder and SAD, but side effects and 
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the need to follow dietary restrictions limit its use, and it should only be considered when patients have not 
responded to or proved intolerant of other treatment approaches. Moclobemide has some efficacy in panic 
disorder and social phobia, and the reversibility of its action reduces the need for dietary restrictions.  
 
 
 
Benzodiazepines 
Some benzodiazepines have proven efficacy in panic disorder, GAD and social phobia, but they can cause 
troublesome sedation in acute treatment, and dependence can occur (especially in predisposed patients) 
with longer-term use (Royal College of Psychiatrists, 2005). Discontinuation symptoms have their peak 
severity at 2 days for short half-life and 4-7 days for long-half life benzodiazepines (Rickels et al., 1990). 
As they have limited efficacy in relieving depressive symptoms (Ib) (Rickels et al., 1991), antidepressants 
should be preferred in patients with significant co-morbid depression. Benzodiazepines will usually be 
reserved for the treatment of patients who have not responded to at least two treatments (such as after non-
response to both an SSRI and a psychological treatment) but concerns about potential problems in long 
term use should not prevent their use in patients with persistent, severe, distressing, and impairing anxiety 
symptoms (Nutt, 2005b).  
 
Other agents 
The side effect burden and currently limited evidence base for antipsychotic drugs in the treatment of 
anxiety disorders (with efficacy mainly for certain antipsychotics after non-response to SSRI treatment in 
OCD) means they have only a limited role in overall patient management (El-Khayat and Baldwin, 1998). 
Certain non-benzodiazepine anticonvulsant drugs have proven efficacy in some anxiety disorders 
(principally GAD and social phobia) but there have been few randomised controlled trials and the potential 
for development of tolerance or dependence with prolonged use in anxiety disorders is not certain (Ashton 
and Young, 2003): for these reasons, anticonvulsants would normally be restricted for use in patients who 
have not responded to or proved intolerant of treatments with a more substantial evidence base.  
 
 
Psychological treatments 
Many patients have a preference for psychological treatments over pharmacological approaches. Certain 
forms of psychotherapy, such as exposure therapy, cognitive therapy and cognitive-behaviour therapy 
(CBT), have proven efficacy in the treatment of anxiety disorders; but others, such as psychodynamic 
psychotherapy, have not been found superior to control interventions, or have not been subject to controlled 
investigations. Many evaluations of the efficacy of psychological treatments have not employed an optimal 
psychological placebo control treatment: the use of waiting list controls is inadequate. As with 
pharmacological approaches, it should be emphasised that response is not immediate; that transient 
 10
worsening of symptoms can sometimes occur; that prolonged courses are often needed to maintain an 
initial treatment response; that dependence on the therapist may occur, with problems when treatment is 
stopped; and that encouraging short-term outcomes are no guarantee of good outcomes over the longer-
term. 
 
In general, the efficacy of psychological and pharmacological approaches is similar in the acute treatment 
of anxiety disorders. In some studies, relapse rates are lower after an initial response to cognitive therapy 
with exposure than after response to drug treatment. For these reasons, patients should be offered a choice 
of treatment approaches, selection being affected by patient clinical features, needs and preference, and by 
the local availability of services able to offer evidence-based psychological interventions. It is uncertain 
whether combining psychological and pharmacological treatments is associated with greater efficacy, than 
either treatment given alone. As such it may be best to plan sequential steps in patient management 
(National Institute for Clinical Excellence, 2004).  Previous concerns that prescription of psychotropic 
drugs might reduce the efficacy of psychological treatment are probably unfounded (Lader and Bond, 
1998).  
 
When psychological treatment is recommended, it should be only be delivered by suitably trained and 
supervised staff, able to demonstrate that their clinical practice adheres to evidence-based treatment 
protocols (National Institute for Clinical Excellence, 2004). The relative scarcity of such individuals 
reduces the range of treatment options open to patients and doctors.   
 
 
A general range of 8-20 hours of sessions of CBT may be needed in the treatment of anxiety disorders. In 
GAD and panic disorder, a typical treatment course consists of approximately 16-20 hours, up to half of 
which can be conducted by the patient in supervised ‘homework’ sessions, over a period of approximately 
four months (National Institute for Clinical Excellence, 2004). In PTSD, a standard course of psychological  
treatment might involve 8-12 sessions of trauma-focused CBT, delivered at weekly intervals (National 
Institute for Clinical Excellence, 2005). In OCD, a typical initial treatment course might include 
approximately 16 hours of intervention based on exposure and response prevention, with longer and more 
intensive treatment in housebound patients (National Institute for Clinical Excellence, 2005).  
 
 
The role of self-help and other approaches in anxiety disorders 
Patient preference and the sub-optimal effects of pharmacological or psychological treatment approaches 
have encouraged the development of a range of self-help techniques and therapies in anxiety disorders. 
Many patients and their carers derive considerable support from local self-help groups and national self-
help organisations (such as the United Kingdom organisations the National Phobics Society, No Panic, and 
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Obsessive Action). There have been relatively few randomised controlled trials of the efficacy and 
acceptability of self-help approaches and few studies have been conducted in diagnostically homogenous 
groups, with reliable outcome measures and robust statistical analysis.  
 
A systematic review of six randomised controlled trials indicates that self-help is efficacious in primary 
care patients with mixed anxiety disorders, greater efficacy being seen with more detailed instruction in use 
of self-help manuals (Ia) (van Boeijen et al., 2005). Bibliotherapy (use of self-help books) appears 
efficacious in patients with ‘clinically significant emotional disorders’, but the efficacy of self-help groups 
in this population is not established (Ia) (den Boer et al., 2004). A systematic review of complementary 
therapies finds some evidence for the efficacy of bibliotherapy (in specific phobia), relaxation training (in 
GAD and panic disorder), exercise (in GAD) and use of Kava [now withdrawn due to hepatotoxicity] (in 
GAD) (Ia) (Jorm et al., 2004). A systematic review of counselling for primary care patients with emotional 
problems (including anxiety, depression, and ‘stress’) indicates that the short-term (but not long-term) 
efficacy of counselling was greater than that of standard general practitioner care, with or without 
antidepressant treatment (Ia) (Bower et al., 2001).  
 
In discrete anxiety disorders, there is some evidence for the efficacy of a broad range of interventions, 
including bibliotherapy (Ib) (Lidren et al., 1994), exercise therapy (Ib) (Broocks et al., 1998) and Internet-
based computerised cognitive therapy (Ib) (Carlbring et al., 2003) in panic disorder; and computer-guided 
behaviour therapy (Ib) (Greist et al., 2002) and possibly yogic meditation (Ib) (Shannahoff-Khalsa et al., 
1999) in OCD. The efficacy of self-help techniques in other anxiety disorders has not been examined 
extensively:  it was no more efficacious than repeated assessment in post-traumatic stress disorder (Ehlers 
et al., 2003). The UK National Institute for Clinical Excellence concluded that there was insufficient 
evidence to recommend the general introduction of computerised cognitive behaviour therapy for anxiety 
symptoms or disorders (Ia) (NICE, 2002).  
 
Cost-effectiveness of treatment 
Anxiety disorders are associated with a substantial economic burden, both for the health system and 
(especially) for the wider society in terms of productivity losses (I) (Souetre et al., 1994; Salvador-Carulla 
et al., 1995; Rice and Miller, 1998; Greenberg et al., 1999; Andlin-Sobocki & Wittchen, 2005), but there 
have been few evaluations of the cost-effectiveness of treatment in anxiety disorders. Treatment costs 
account for a small proportion of the overall costs of health care (Durham et al , 2005). An economic 
evaluation of the cost-effectiveness of differing forms of secondary care provision for Vietnam veterans 
with PTSD found higher levels of patient satisfaction, reduced overall costs and reduced likelihood of 
symptomatic relapse with short-stay, compared to long-stay inpatient provision (Ib) (Fontana and 
Rosenheck, 1997). A randomised controlled trial of a collaborative care intervention (education, surgery 
visits from a psychiatrist) in United States primary care patients with panic disorder found that patients 
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subject to such intervention experienced proportionately more anxiety-free days over 12 months at reduced 
overall costs compared to a ‘treatment as usual’ control group (Ib) (Katon et al., 2002).  A randomised 
controlled trial of computerised CBT versus standard care in United Kingdom primary care patients with 
depression and/or anxiety disorders found that outcomes were improved (Ib) (Proudfoot et al., 2004), 
service costs were higher but lost employment costs lower in the intervention group (Ib) (McCrone et al., 
2004). The computerised CBT appeared to be cost-effective by broad (health system-wide and societal) 
criteria. Decision modeling indicates that venlafaxine is more cost-effective than diazepam in the treatment 
of generalised anxiety disorder (IIb)(Guest et al., 2005). In general, economic models suggest that 
evidence-based treatment of anxiety disorders would produce greater population health gain at a similar 
cost to current care (II) (e.g. Patel et al., 2002; Issakidis et al., 2004; NICE, 2005) – consequences which 
are likely to be seen as a cost-effective use of resources.  
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GENERALISED ANXIETY DISORDER (GAD) 
Recognition and diagnosis 
Although generalised anxiety disorder (GAD) is amongst the most common mental disorders in primary 
care, and is associated with increased use of health services, it is often not recognized (I); possibly because 
only a minority of patients present with anxiety symptoms (most patients with present physical symptoms), 
and doctors tend to overlook anxiety unless it is a presenting complaint (I) (Ormel et al., 1990). The 
disability associated with GAD is similar to that with major depression (I) (Wittchen et al, 2000). Patients 
with ‘co-morbid’ depression and GAD have a more severe and prolonged course of illness and greater 
functional impairment (I) (Kessler et al., 1999), and a greater chance of being recognized as having mental 
health problems, though not necessarily as having GAD (Weiller et al., 1998; Wittchen et al, 2002). 
 
Acute treatment 
Systematic reviews and placebo-controlled RCTs indicate that some SSRIs (escitalopram, paroxetine and 
sertraline), the SNRI venlafaxine, some benzodiazepines (alprazolam and diazepam), the tricyclic 
imipramine, and the 5-HT1A partial agonist buspirone are all efficacious in acute treatment (Ia) (National 
Institute for Clinical Excellence, 2004; Baldwin and Polkinghorn, 2005; Kapczinski et al., 2003, Mitte et 
al., 2005). Other compounds with proven efficacy (Ib) include the antipsychotic trifluoperazine (Mendels et 
al., 1986), the antihistamine hydroxyzine (Lader and Scotto, 1998; Llorca et al., 2002), the anticonvulsant 
pregabalin (Feltner et al., 2003), and the sigma-site ligand opipramol (Möller et al., 2001). Treatments with 
unproven efficacy in GAD include the beta-blocker propranolol (Ib) (Meibach et al., 1987).  
 
There have been few comparator-controlled studies, and most reveal no significant differences in efficacy 
between active compounds (Mitte et al., 2005): however, escitalopram (20 mg/day) has been found 
significantly superior to paroxetine (20 mg/day) (Ib) (Baldwin et al., 2004), and venlafaxine (75-225 
mg/day) superior to fluoxetine (20-60 mg/day) on some outcome measures in patients with co-morbid 
GAD and major depression (Ib) (Silverstone and Salinas, 2001). Psychological symptoms of anxiety may 
respond better to antidepressant drugs than to benzodiazepines (Baldwin and Polkinghorn, 2005; Meoni et 
al, 2004). Fixed-dose RCTs provide some evidence of a dose-response relationship with escitalopram, 
paroxetine and venlafaxine (Ib) (Baldwin et al., 2004; Rickels et al., 2003; Allgulander et al., 2001; Rickels 
et al., 2000).   
 
Long term treatment 
Double-blind studies indicate that continuing with SSRI or SNRI treatment is associated with an increase in 
overall response rates (Ib): from 8 to 24 weeks with escitalopram or paroxetine (Bielski et al., 2004); from 
4 to 12 weeks with sertraline (Allgulander et al., 2004) and from 8 to 24 weeks with venlafaxine 
(Montgomery et al., 2002). Placebo-controlled relapse-prevention studies in patients who have responded 
to previous acute treatment reveal a significant advantage for staying on active medication (escitalopram or 
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paroxetine), compared to switching to placebo, for up to six months (Ib) (Stocchi et al., 2003; Allgulander 
et al., 2005).  
 
Comparative efficacy of psychological, pharmacological, and combination treatments 
Drug or psychological treatments, delivered singly, have broadly similar efficacy in acute treatment (Ia) 
(National Institute for Clinical Excellence, 2004; Gould et al., 1997). Relapse rates are lower with cognitive 
behaviour therapy than with other forms of psychological treatment (Ib) (Fisher and Durham, 1999; 
Durham et al., 2003), but the comparative efficacy of drug and psychological approaches over the long-
term is not established. It is uncertain whether combining drug and psychological treatments is associated 
with greater overall efficacy than with either treatment, given alone (Ib) (Lader and Bond, 1998; Power et 
al., 1990; Durham and Turvey, 1987).  
 
When initial treatments prove unhelpful 
There is no clear evidence for an increase in response with dose escalation after an initial non-response to a 
lower dose. Switching between treatments with proven efficacy may be helpful (National Institute for 
Clinical Excellence, 2004).  
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PANIC DISORDER (with and without agoraphobia) 
Recognition and diagnosis 
Patients with panic disorder are often not recognized in primary or secondary medical care, despite their 
considerable use of emergency, cardiac, gastrointestinal, neurological and mental health services (I) (Roy-
Byrne et al., 1999). There is considerable co-morbidity with other anxiety disorders, bipolar disorder and 
major depression; co-morbid panic and depression being associated with greater disability and impairment, 
and increased use of health services (I) (Roy-Byrne et al., 2000). Accurate diagnosis is dependent upon 
establishing the presence of initially unexpected panic attacks (with comparative freedom from anxiety 
between attacks) and the associated concern, worry or change in behaviour due to the anticipated risk of 
further attacks. In primary and secondary medical care, very few patients fulfill diagnostic criteria for 
agoraphobia without panic disorder; in coexisting panic and agoraphobia, some (II) (Langs et al., 2000; 
Goisman et al., 1995) but not all (II) (Amering et al., 1997; Lelliott et al., 1989) studies suggest 
agoraphobia is a consequence of the severity of a primary panic disorder. 
 
Acute treatment 
Systematic reviews demonstrate that a range of pharmacological, psychological and combination 
interventions are effective in panic disorder (Ia) (Van Balkom et al., 1997; Bakker et al., 1998). 
Randomised double-blind placebo-controlled trials of antidepressants indicate that all SSRIs (Ia) 
(escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline); some TCAs (Ia) 
(clomipramine, imipramine); and some benzodiazepines (Ia) (alprazolam, clonazepam, diazepam and 
lorazepam) are efficacious in acute treatment (Otto et al., 2001; Den Boer, 1998). Other antidepressants 
with proven efficacy include the SNRI venlafaxine (Ib) (Pollack et al., 2004), the selective noradrenaline 
reuptake inhibitor reboxetine (Ib) (Versiani et al., 2002), and the MAOI brofaromine (no longer in 
development) (Ib) (Van Vliet et al., 1993).  
 
Comparator-controlled studies provide some evidence for efficacy of mirtazapine (Ib)(Ribeiro et al., 2001) 
and moclobemide (Ib) (Tiller et al., 1999); and suggest that escitalopram is superior to citalopram (Ib) 
(Stahl et al., 2003), and some SSRIs (paroxetine, fluvoxamine) to some noradrenaline reuptake inhibitors 
(reboxetine, maprotiline) (Ib) (Bertani et al., 2004; Den Boer et al., 1988). The side effect burden 
associated with SSRI treatment in panic disorder is somewhat less than that with other classes of 
psychotropic drug (Ib) (Baldwin and Birtwistle, 1998). Treatments with unproven efficacy in panic disorder 
include the beta-blocker propranolol (Ib) (Munjack et al., 1989); buspirone (Ib) (Sheehan et al., 1988); and 
antihistamines or antipsychotics (IV) (National Institute for Clinical Excellence, 2004). Fixed-dose RCTs 
with SSRIs provide only limited evidence of a dose-response relationship, for fluoxetine (Ib) (Michelson et 
al., 1998); and for paroxetine (Ib) (Ballenger et al., 1998). 
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Long-term treatment 
Double-blind studies indicate that continuing SSRI or clomipramine treatment from 12 weeks to 52 weeks 
is associated with an increase in overall treatment response rates (Ib) (Lecrubier and Judge, 1997; Lepola et 
al., 1998), (IV) (Ballenger et al., 1998). Placebo-controlled and other relapse-prevention studies in patients 
who have responded to previous acute treatment reveal a significant advantage for staying on active 
medication (fluoxetine, paroxetine, sertraline, imipramine), compared to switching to placebo for up to six 
months (Ib) (Michelson et al., 1999; Dannon et al., 2004; Rapaport et al., 2001; Mavissakalian and Perel, 
1999).  
 
Comparative efficacy of psychological, pharmacological, and combination treatments 
Pooled analyses and randomised controlled trials indicate that drug and psychological treatments, delivered 
singly, have broadly similar efficacy in acute treatment, and suggest CBT may be superior to TCAs in 
preventing symptomatic relapse (Ia) (Van Balkom et al., 1997). Overall, it is uncertain whether combining 
drug and psychological treatments is associated with greater overall efficacy than with either treatment, 
given alone (Ia) (Ib) (Van Balkom et al., 1997; Barlow et al., 2000). Combination treatment with exposure 
was superior to imipramine given alone (Mavissakalian et al., 1983). Combination treatment with 
paroxetine was superior to psychological treatment alone, in studies of bibliotherapy (Ib) (Dannon et al., 
2002), ‘very brief’ CBT (Ib) (Stein et al., 2000) and basic CBT (Ib) (Oehrberg et al., 1995); and buspirone 
may enhance the short-term efficacy of CBT (Ib) (Cottraux et al., 1995).  
 
When initial treatments prove unhelpful 
There is no clear evidence for the benefit of dose escalation after an initial non-response to low doses. 
Switching between treatments with proven efficacy may be helpful (National Institute for Clinical 
Excellence, 2004). Augmentation of CBT with paroxetine may be superior to continuing with CBT alone, 
in patients who did not previously respond over 15 sessions (Kampmann et al., 2002); and augmentation of 
fluoxetine with pindolol was superior to continued monotherapy with fluoxetine (Hirschmann et al., 2000). 
The addition of group CBT may be beneficial in non-responders to pharmacological approaches (Otto et 
al., 1999; Pollack et al., 1994; Heldt et al., 2003). There is only limited evidence for augmentation 
strategies involving benzodiazepines, mood stabilizers or antipsychotic drugs. 
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SOCIAL PHOBIA (also known as social anxiety disorder) 
Recognition and diagnosis 
Social phobia is often not recognized in primary medical care (I), where it is often misconstrued as shyness 
(Weiller et al., 1996). It can be distinguished from shyness by the levels of personal distress and associated 
social and occupational impairment (I) (Stein et al., 2000). The generalised sub-type is associated with 
greater disability and higher co-morbidity but patients with the non-generalised form can also be 
substantially impaired (I) (Kessler et al., 1998; Eng et al., 2000). Distinguishing social phobia from 
avoidant personality disorder is difficult and many patients fulfill diagnostic criteria for both conditions (I) 
(McGlashan et al., 2000). Patients can present with symptoms arising from co-morbid conditions 
(especially depression), rather than with characteristic social anxiety and avoidance (IV) (Lecrubier et al, 
2000).  Many patients use alcohol and drugs of misuse in an attempt to relieve symptoms (I) (Patel et al, 
2002). 
 
 
Acute treatment 
Systematic reviews and placebo-controlled RCTs indicate that a range of treatment approaches are 
efficacious: including CBT (Ia) (Heimberg, 2002), SSRIs (escitalopram, fluoxetine, fluvoxamine, 
paroxetine and sertraline), the SNRI venlafaxine, the MAOI phenelzine, and the RIMA moclobemide. 
Some benzodiazepines (bromazepam and clonazepam) and anticonvulsants (gabapentin and pregabalin) 
and the antipsychotic olanzapine are also efficacious in acute treatment (Ia) (Blanco et al., 2003); (Ib) 
(Pande et al., 2004; Davidson et al., 2004[a]; Davidson et al., 2004[b]; Lader et al., 2004). Treatments with 
unproven efficacy in generalised social phobia include the TCA imipramine, buspirone, and the beta-
blocker atenolol (Ib) (Blanco et al., 2003). There have been few comparator-controlled studies: 
escitalopram (20 mg/day) has been found superior to paroxetine (20 mg/day) (Lader et a.l, 2004), whereas 
venlafaxine (75-225 mg/day) and paroxetine (20-50 mg/day) had similar efficacy in two placebo-controlled 
studies (Allgulander et al., 2004; Liebowitz et al., 2005). Fixed-dose RCTs do not provide convincing 
evidence of a dose-response relationship (Ib) (Liebowitz et al., 2002; Lader et al., 2004).  Post-hoc analysis 
of the RCT database with paroxetine indicates that many non-responders to treatment at eight weeks 
become responders with four further weeks of double-blind treatment (Stein et al., 2002).   
 
Long-term treatment 
Double-blind studies indicate that continuing SSRI or SNRI treatment from 12 weeks to 24 weeks is 
associated with an increase in overall treatment response rates (Ib) (Stein et al., 2003; Lader et al., 2004; 
Stein et al., 2005). Placebo-controlled relapse-prevention studies in patients who have responded to 
previous acute treatment reveal a significant advantage for staying on active medication (clonazepam, 
escitalopram, paroxetine, sertraline), compared with switching to placebo for up to six months (Ib) (Blanco 
et al., 2003).  
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Comparative efficacy of pharmacological, psychological and combination treatments 
Drug and psychological treatments, delivered singly, have broadly similar efficacy in acute treatment (Ia) 
(Heimberg et al, 1998; Otto et al., 2000; Blomhoff et al., 2001; Davidson et al., 2004). However, acute 
treatment with cognitive therapy (group or individual) may be associated with reduced risk of symptomatic 
relapse at follow-up (Ib) (Liebowitz et al., 1999; Clark et al., 2003; Haug et al., 2003). It is uncertain 
whether combining drug and psychological treatments is associated with greater overall efficacy than with 
either treatment, given alone (Ib) (Blomhoff et al., 2001; Clark et al., 2003; Davidson et al., 2004). 
 
When initial treatments prove unhelpful 
There is no clear evidence for the benefit of dose escalation after an initial non-response. Switching 
between treatments with proven efficacy may be helpful (IIb) (Altamura et al., 1999). Open-label 
augmentation of SSRI treatment with buspirone has been reported as beneficial (IIb) (Van Ameringen et 
al., 1996), but a placebo-controlled pindolol augmentation study with paroxetine treatment indicates that 
the addition of pindolol was not associated with greater treatment efficacy (Ib) (Stein et al., 2001).  
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SIMPLE PHOBIA (also known as specific [or isolated] phobia) 
Recognition and diagnosis 
Specific fears of objects, animals, people or situations are widespread (having a lifetime prevalence of 
49.5% in the National Co-morbidity Survey), but only a minority (24.2%) of affected individuals reach 
diagnostic criteria for simple phobia (I) (Kessler et al., 1994). The presence of multiple fears is associated 
with increasing impairment, and co-morbidity with other anxiety disorders (I) (Kessler et al., 1994). Many 
patients with specific fears only present for treatment at the time of changes in domestic or occupational 
responsibilities.  
 
Treatment 
Most specific fears respond to simple psychological approaches, based on exposure techniques. In vivo 
exposure with participant modelling appears superior to imaginal exposure (Ib) (Ost et al., 1997). Most 
patients respond to psychological approaches, and only few will require other treatment interventions (D). 
Limited data suggest that paroxetine (Ib) (Benjamin et al., 2000) and some benzodiazepines (III) 
(Uhlenhuth et al., 1999) are efficacious in acute treatment of simple phobia. It is unclear whether 
concomitant use of benzodiazepines enhances or reduces the efficacy of behavioural approaches.  
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POST-TRAUMATIC STRESS DISORDER (PTSD) 
Recognition and diagnosis 
The findings of the US National Comorbidity Survey indicate that exposure to traumatic events was 
common (60.7% of men and 51.2% of women reported exposure to at least one traumatic event) but post-
traumatic stress disorder (PTSD) had a lower lifetime prevalence (7.8%) indicating that many are resilient 
to traumatic adversity (I) (Kessler et al., 1995). It shows considerable co-morbidity with other anxiety 
disorders, depression, and alcohol abuse or dependence, and is associated with increased use of health 
services, but is often not recognized in primary or secondary care, possibly due to unfamiliarity with the 
diagnostic criteria. Diagnosis can be established through a history of exposure to trauma (actual or 
threatened death, serious injury, or threats to the physical integrity of the self or others); a response of 
intense fear, helplessness or horror; re-experiencing symptoms (commonly intrusive recollections, 
flashbacks or dreams); avoidance symptoms (such as efforts to avoid activities or thoughts associated with 
the trauma); and hyper-arousal symptoms (including disturbed sleep, hypervigilance and an exaggerated 
startle response).  
 
Prevention of post-traumatic symptoms 
There is theoretical scope for preventing the emergence of post-traumatic symptoms in people subject to 
major trauma. Acute administration of propranolol (160 mg/day) was superior to placebo in reducing 
subsequent post-traumatic symptoms and physiological hyper-activity to reminders of trauma, but not the 
emergence of PTSD, at 1 month (Ib) (Pitman et al., 2002); and a naturalistic study suggests acute 
administration of propranolol (120 mg/day) prevented the emergence of syndromal PTSD at 2 months (IIa) 
(Vaiva et al., 2003). Acute intravenous administration of hydrocortisone was superior to placebo in 
preventing emergence of post-traumatic symptoms, both in intensive care patients with septic shock 
(median interval, 31 months), and in patients undergoing cardiac surgery (interval, 6 months) (Ib) 
(Schelling et al., 2001; 2004). By contrast, early administration of benzodiazepines after trauma may not 
prevent the emergence of post-traumatic symptoms (IIa) (Gelpin et al, 1996). The psychological approach 
with best evidence of efficacy in prevention of chronic post-traumatic symptoms is trauma-focused CBT, 
when provided within 6 months of the incident (Ia): approaches with limited efficacy include debriefing, 
relaxation and supportive psychotherapy (National Institute for Clinical Excellence, 2004). 
 
Acute treatment of chronic PTSD 
Systematic reviews demonstrate that a range of pharmacological and psychological approaches are 
efficacious in acute treatment of PTSD (Ia) (Van Etten and Taylor, 1998; Friedman et al., 2000; Stein et al., 
2004; National Institute for Clinical Excellence, 2005). Randomised placebo-controlled trials provide 
evidence for the efficacy of some antidepressants (the SSRIs fluoxetine, paroxetine and sertraline; the 
TCAs amitriptyline and imipramine; the MAOIs phenelzine and brofaromine; and mirtazapine) on some 
outcome measures (Ia), but the clinical relevance of drug-placebo differences is debatable (National 
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Institute for Clinical Excellence, 2005). In addition, there is evidence for the efficacy of venlafaxine (Ib) 
(Davidson et al., 2004), nefazodone (Davis et al, 2004) and the anticonvulsant lamotrigine (Ib) (Hertzberg 
et al., 1999). A comparator- and placebo-controlled study suggests phenelzine was superior to imipramine, 
in relieving avoidance symptoms (Ib) (Kosten et al., 1991). It is uncertain whether there is a dose-response 
relationship with any of the compounds with evidence of efficacy. Psychological approaches with proven 
efficacy include individual trauma-focused CBT and eye movement desensitization and reprocessing 
(EMDR) (Ia) (Van Etten and Taylor, 1998; National Institute for Clinical Excellence, 2005). Non trauma-
focussed psychological treatments and group therapies have not been shown to have proven efficacy, but 
neither have they been shown to be harmful (Ia) (National Institute for Clinical Excellence, 2005).  
 
Long-term treatment 
After a response to acute treatment, continuing with venlafaxine (Ib) (Davidson et al., 2004) or sertraline 
(IIb) (Londborg et al., 2001) treatment over 6 months is associated with a gradual increase in overall 
treatment response. Placebo-controlled relapse-prevention studies in patients who have responded to 
previous acute treatment reveal a significant advantage for staying on active medication, for fluoxetine (Ib) 
(Martenyi et al., 2002; Davidson et al, 2005) and sertraline (Ib) (Davidson et al., 2001).  
 
Comparative efficacy of psychological and drug treatments 
There have been very few direct comparisons of the efficacy of psychological and pharmacological 
treatments, in either acute or long-term treatment. A small unblinded 12-week comparison of paroxetine 
and trauma-focused CBT (IIa) (Frommberger et al., 2004) suggested that CBT may have certain 
advantages, in reducing post-traumatic and depressive symptoms.  
 
When initial treatments prove unhelpful 
There is no clear evidence for dose escalation after an initial non-response. Switching between treatments 
with proven efficacy may be helpful although there is little evidence (National Institute for Clinical 
Excellence, 2005). In placebo-controlled augmentation studies in patients who have not responded to 
antidepressant treatment, there is evidence for the efficacy of the atypical antipsychotic drugs olanzapine 
(Ib) (Stein et al., 2002) and risperidone (in patients with co-existing psychotic symptoms, or aggression) 
(Ia) (Hamner et al., 2003; Monelly et al., 2003).  An uncontrolled small study suggests that augmentation 
with the anticonvulsant tiagabine may be beneficial, after initial non-response (IIb) (Taylor, 2003).  
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OBSESSIVE-COMPULSIVE DISORDER (OCD) 
Recognition and diagnosis 
Obsessive-compulsive disorder has a lifetime prevalence of approximately 2.0% (I) (Weissman et al., 
1994). The content of obsessions varies little between countries or cultures (I) (Sasson et al., 1997). The 
disorder typically follows a chronic course, waxing and waning in severity; and substantial co-morbidity 
with major depression and anxiety disorders(I) (Rasmussen and Eisen, 1990) and tic disorders (I) (Zohar et 
al., 1992). Distinguishing OCD from obsessive-compulsive personality disorder is difficult and patients 
may fulfill diagnostic criteria for both conditions (I) (Albert et al., 2004). Patients can present with 
symptoms arising from co-morbid conditions (especially bipolar disorder and major depression), rather 
than with obsessional ruminations and compulsive rituals (IV) (Angst et al, 2000).  
 
Acute treatment 
Systematic reviews and meta-analyses of randomised placebo-controlled trials indicate that the TCA 
clomipramine and the SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) are 
efficacious in acute treatment. Psychological approaches with proven efficacy in acute treatment include 
behaviour therapy based on exposure techniques and cognitive therapy (Ia) (Kobak et al., 1998).  
 
The efficacy of clomipramine appears marginally superior to that of SSRIs in meta-analysis (Ia) (Ackerman 
and Greenland, 2002); though not in randomised controlled trials, in which the tolerability of SSRIs is 
generally superior (Ia) (Fineberg and Gale, 2005).  
 
Fixed-dose comparator studies provide inconsistent evidence for a dose-response relationship with SSRIs, 
higher doses being associated with greater efficacy in some (Ib) (Montgomery et al., 1993; Wheadon et al., 
1993, Hollander et al., 2003) but not all evaluations (Ib) (Tollefson et al., 1994; Greist et al., 1995; 
Montgomery et al., 2001).  
 
Long term treatment 
Long-term (up to 12 months) double-blind studies demonstrate an advantage for continuing with 
medication, in patients who have responded to acute treatment (Ib) (Katz et al., 1990; Tollefson et al., 
1994; Greist et al., 1995). Most (but not all) placebo-controlled relapse-prevention studies in patients who 
have responded to previous acute treatment reveal a significant advantage for staying on active medication 
(clomipramine; paroxetine; sertraline; and fluoxetine, at higher dose), compared to switching to placebo 
(Ia) (Fineberg and Gale, 2005).  
 
Comparative efficacy of psychological and drug treatments 
There is some evidence that combination treatment is superior to psychological approaches or serotonergic 
antidepressant treatment, when given alone. The evidence for enhanced efficacy of exposure therapy with 
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clomipramine compared to exposure alone is inconsistent (Ib) (Marks et al., 1988; Foa et al., 2005), but 
fluvoxamine has been shown to enhance the efficacy of exposure therapy (Ia) (Cottraux et al., 1993) and 
multi-modal CBT (Ia) (Hohagen et al., 1998). Some studies have suggested that relapse rates are greater 
after initial treatment with a pharmacological rather than with a psychological intervention (Ib) (Simpson et 
al., 2004). 
 
When initial treatments prove unhelpful 
Switching between pharmacological or psychological treatments with proven efficacy may be helpful in 
some patients, as may increasing dosage, tolerability permitting. Randomised double-blind or single-blind 
(Atmaca et al., 2002) placebo-controlled augmentation studies indicate that haloperidol (Ib) (McDougle et 
al., 1994), risperidone (Ib) (McDougle et al., 2000; Hollander et al., 2003; Erzegovesi et al., 2005) and 
quetiapine (Ib) (Atmaca et al., 2002; Denys et al., 2004) are all efficacious in patients who have not 
responded to initial treatment with SSRIs: the evidence for augmentation with pindolol is mixed (Ib) (Blier 
and Bergeron, 1996; Dannon et al., 2000). Intravenous infusion of clomipramine also appears efficacious 
after non-response to oral clomipramine, but the necessary arrangements for monitoring limit its usefulness 
in clinical practice (Fallon et al., 1998). By contrast, placebo-controlled or comparator-controlled (Pigott et 
al., 1991) studies indicate that augmentation treatment with lithium (Ib) (McDougle et al., 1991; Pigott et 
al., 1991), buspirone (Ib) (Pigott et al., 1992; Grady et al., 1993), liothyronine (Ib) (Pigott et al., 1991), 
desipramine (Ib) (Barr et al., 1997) or inositol (Ib) (Fux et al., 1999) is not efficacious. Potential but as yet 
not fully proven approaches in treatment-resistant OCD include higher-dose SSRI monotherapy; 
combination SSRI-clomipramine treatment; augmentation with other atypical antipsychotics, CNS-
penetrating triptans, immunoglobulins and plasmapharesis (IV) (Husted and Shapira, 2004). Other potential 
approaches include deep brain stimulation (IIb) (Nuttin et al., 2003); and neurosurgical approaches, 
including anterior capsulotomy, limbic leucotomy and cingulotomy (III) (Royal College of Psychiatrists, 
2000). 
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SPECIAL CONSIDERATIONS 
Children and adolescents 
Certain anxiety disorders (social phobia and obsessive-compulsive disorder) have a typical age of onset of 
symptoms in adolescence, and many young people are substantially disabled by distressing, persistent and 
severe anxiety symptoms (I) (Rasmussen and Eisen, 1990; Faravelli et al., 2000; Weissman et al., 1994). 
There have been comparatively few controlled evaluations of the benefits and risks of psychotropic drug 
treatment in young people, but randomised placebo-controlled trials in children and adolescents indicate 
that SSRIs and clomipramine are efficacious in OCD (Ib) (Geller et al., 2003), and paroxetine in social 
phobia (Ib) (Wagner et al., 2004). The treatment response in OCD is similar in adult (18-65 years) and 
younger (6-17 years) clinical samples (Ia) (Fineberg et al., 2004). 
 
The United Kingdom Committee on Safety of Medicines has stated that the balance of risks and benefits 
for the treatment of depressive illness in people under the age of 18 years is judged to be unfavourable for 
some SSRIs (escitalopram, citalopram, paroxetine and sertraline), mirtazapine and venlafaxine (IV) 
(Committee on Safety of Medicines, 2004), and has advised caution when treating adults aged 18-30 years 
with SSRIs. These recommendations do not apply to the treatment of children and adolescents with anxiety 
disorders, because the risk of self-harm is less and the therapeutic benefits greater. Nevertheless, careful 
monitoring is advisable, due to possible diagnostic uncertainty, the presence of co-morbid depression, 
problems associated with estimating the optimal dosage, and the difficulties young people might have in 
describing untoward effects of psychotropic drug treatment. It may be preferable to reserve 
pharmacological treatments for patients who do not respond to evidence-based psychological approaches. 
 
Elderly patients 
Many elderly patients are troubled by anxiety symptoms, though anxiety disorders in those over 65 years 
may be less common than in younger samples (I) (Flint, 1994; Schaub and Linden, 2000), and there have 
been few controlled investigations in this patient group. Placebo-controlled studies indicate that venlafaxine 
is efficacious in elderly patients with GAD (Ia) (Katz et al., 2002), and citalopram in patients with a range 
of anxiety disorders (Ib) (Lenze et al., 2005).  
 
Pharmacological treatment of anxiety disorders in patients with cardiac disease or epilepsy 
TCAs are best avoided in patients with cardiac disease: they can increase heart rate, induce orthostatic 
hypotension, slow cardiac conduction, and have significant quinidine-like effects on conduction within the 
myocardium. Other type 1A antiarrhythmics (quinidine, moricizine) carry an increased risk of mortality in 
patients with ventricular arrhythmias and ischaemic heart disease, and TCAs should be regarded as 
relatively contraindicated in these situations: by contrast, the SSRIs have minimal effects on cardiovascular 
function and may have potentially beneficial effects on platelet aggregation (Davies et al., 2004; Roose, 
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2003). The UK CSM currently recommends that venlafaxine is avoided in patients with cardiac disease, 
electrolyte imbalances or hypertension (IV) (Committee on Safety of Medicines, 2004).  
 
Most antidepressants can lower the seizure threshold. The antidepressants amoxapine and maprotiline (and 
bupropion, marketed in the US as an antidepressant) probably have the most marked proconvulsant 
properties and should be avoided in epileptic patients (Kanner, 2003): the lack of evidence of efficacy in 
anxiety disorders means prescription of these drugs should be avoided. Pharmacokinetic interactions 
between antidepressants and anticonvulsants are not uncommon – for example, carbamazepine can increase 
the metabolism of TCAs, whereas fluoxetine can inhibit the metabolism of some anticonvulsants: it is 
always advisable to establish the potential for untoward drug-drug interactions when treating epileptic 
patients with anxiety disorders.  
 
Pregnant and breastfeeding women 
In general, most doctors would consider withdrawing psychotropic drugs in pregnant women (particularly 
in the first trimester), but it is sometimes necessary to continue treatment, in patients with severe anxiety 
disorders. Many studies have indicated that TCAs and fluoxetine may be safe when taken during the first 
trimester, but their potential teratogenicity and effects on development after delivery is less certain. The 
findings of a prospective controlled study suggest that long-term pre-natal exposure to fluoxetine or TCAs 
does not adversely affect cognition, language development or temperament (II) (Nulman et al., 2002).  
 
A recent systematic review and pooled analysis indicates that plasma levels of paroxetine and sertraline 
(and the TCA nortriptyline) in breast-fed infants levels are usually undetectable, whereas citalopram and 
fluoxetine produce infant plasma levels that are above 10% of the maternal plasma level (in 22% and 17% 
of infants, respectively) (II) (Weissman AM et al., 2004). The principal concern when treating parents with 
responsibility for infants is probably to avoid the use of excessively sedating compounds (principally 
TCAs, but also mianserin, mirtazapine and trazodone).   
 
Referral to secondary care mental health services 
Patients should be referred to secondary care mental health services when the primary care practitioner 
feels insufficiently experienced to manage the patient’s condition; when two or more attempts at treatment 
have not resulted in sustained improvement; when there are severe coexisting depressive symptoms or a 
risk of suicide; when comorbid physical illness and concomitantly prescribed treatments could interact with 
prescribed psychotropic medication; and when proposed interventions are not available within primary care 
services.  
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Note 
Enquiries about data held by pharmaceutical companies and referenced here should be directed to the 
medical department of the relevant company.  
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Table 1. Categories of evidence and strength of recommendations 
 
Categories of evidence relevant to specific causal relationships and treatments 
Ia Evidence from meta-analysis of RCTs 
Ib Evidence from at least one RCT 
IIa Evidence from at least one controlled study without randomization 
IIb Evidence from at least one other type of quasi-experimental study 
III Evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and 
case-control studies 
IV Evidence from expert committee reports or opinions and/or clinical experience of respected authorities 
 
Proposed categories of evidence for observational findings and associations 
I Evidence from large representative population samples 
II Evidence from small, well designed but not necessarily representative samples 
III Evidence from non-representative surveys, case reports 
IV Evidence from expert committee reports or opinions and/or clinical experience of respected authorities 
 
Strength of recommendations 
A Directly based on category I evidence 
B Directly based on category II evidence or an extrapolated recommendation from category I evidence 
C Directly based on category III evidence or an extrapolated recommendation from category I or II evidence 
D Directly based on category IV evidence or an extrapolated recommendation from category I, II or III 
evidence 
S Standard of clinical care 
 
RCT, randomised controlled trial 
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Table 2.  Short description of the clinical feature of the anxiety disorders  
Derived from the clinical descriptions and diagnostic guidelines in ICD-10 (World Health Organisation, 
1992) and DSM-IV (American Psychiatric Association, 1994). More detailed descriptions are available in 
DSM-IV and ICD-10. 
 
Generalised Anxiety Disorder (GAD) 
Generalised anxiety disorder (GAD) is characterised by excessive and inappropriate worrying that is persistent (lasting 
some months in ICD-10, six months or longer in DSM-IV) and not restricted to particular circumstances. Patients have 
physical anxiety symptoms and key psychological symptoms (restlessness, fatigue, difficulty concentrating, irritability, 
muscle tension and disturbed sleep). Can be co-morbid with major depression (but not arise solely in its context), panic 
disorder, phobic anxiety disorders and OCD in DSM-IV, but must not meet full criteria for these in ICD-10. 
 
Panic Disorder (with or without agoraphobia) 
Panic disorder is characterised by recurrent unexpected surges of severe anxiety (‘panic attacks’), with varying degrees 
of anticipatory anxiety between attacks. Panic attacks are discrete periods of intense fear or discomfort, accompanied 
by at least four physical or psychological anxiety symptoms. Typically panic attacks reach their peak within 10 minutes 
and last around 30-45 minutes. Most patients develop a fear of having further panic attacks. Around two-thirds of 
patients with panic disorder develop agoraphobia, defined as fear in places or situations from which escape might be 
difficult or in which help might not be available, in the event of having a panic attack. These situations include being in 
a crowd, being outside the home, or using public transport (two situations required in ICD-10): they are either avoided 
or endured with significant personal distress (avoidance at some stage is required for ICD-10 diagnosis).  
 
Social Phobia (Social Anxiety Disorder) 
Social phobia is characterised by a marked, persistent and unreasonable fear of being observed or evaluated negatively 
by other people, in social or performance situations, associated with physical and psychological anxiety symptoms. 
Feared situations (such as speaking to unfamiliar people or eating in public) are either avoided or are endured with 
significant personal distress (avoidance must be prominent for ICD-10 diagnosis). 
 
Specific Phobia 
Specific, simple or isolated phobia is characterised by excessive or unreasonable fear of (and restricted to) single 
people, animals, objects, or situations (for example, flying, dentists, seeing blood, etc.) which are either avoided or are 
endured with significant personal distress (avoidance must be prominent for ICD-10 diagnosis). 
 
Post-Traumatic Stress Disorder (PTSD) 
Post-traumatic stress disorder is characterised by a history of exposure to trauma (actual or threatened death, serious 
injury, or threats to the physical integrity of the self or others) with a response of intense fear, helplessness or horror; 
with the later development of re-experiencing symptoms (intrusive recollections, flashbacks or dreams), avoidance 
symptoms (for example efforts to avoid activities or thoughts associated with the trauma), and hyper-arousal symptoms 
(including disturbed sleep, hypervigilance and an exaggerated startle response).  Must usually be within six months of 
the exposure to trauma for an ICD-10 diagnosis. 
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Obsessive-Compulsive Disorder (OCD) 
Obsessive-compulsive disorder is characterised by recurrent obsessional ruminations, images or impulses, and/or 
recurrent physical or mental rituals, which are distressing, time-consuming and cause interference with social and 
occupational function. Common obsessions relate to contamination, accidents, and religious or sexual matters; common 
rituals include washing, checking, cleaning, counting and touching.  
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Table 3.   
Epidemiology of anxiety disorders in the general population based on studies in the EU (Wittchen & 
Jacobi 2005) 
 
Diagnostic group 12-month estimate 
%      (IQR) 
Lifetime estimate (a) 
%      (95% CI) 
Any anxiety disorder  12.0    (11.1 – 13.0) 21.1    (20.5 – 21.6) 
Panic disorder   1.8     (0.7 – 2.2)   3.8     (3.1 – 4.5) 
Agoraphobia (w.o panic)  1.3     (0.7-2.0)  3.8     (3.1 – 4.5) 
GAD   1.7    (0.8 – 2.0)  5.1    (4.3 – 5.9) 
Social phobia  2.3    (1.1 – 4.8)  5.8    (5.1 – 6.5) 
Specific phobia  6.4    (3.4 – 7.6) 13.2   (12.8 – 13.6) 
OCD  0.7    (0.5 – 1.1)   0.8     (0.6 – 1.1) 
PTSD  1.2    (0.9 – 1.3) Not established 
 
Panic disorder (with and without agoraphobia); GAD: Generalised Anxiety Disorder; OCD: Obsessive-
Compulsive Disorder; PTSD: Post-Traumatic Stress Disorder. 
 
The 12-month estimates and interquartile range (IQR) are based upon EU-community studies reporting 
either prevalence estimates for established diagnoses of mental disorders (according to DSM-III, DSM-III-
R, DSM-IV or ICD-10 criteria) or upon studies employing instruments with explicit diagnostic criteria that 
allow such inferences. Lifetime estimates are based on a subset of these studies for which lifetime estimates 
were available (source: Wittchen HU, Jacobi, F (2005). Size and burden of mental disorder in Europe: A 
critical review and appraisal of studies. Eur J Neuropsychopharmacol 15: 357-376).  
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Table 4.   
Distribution of anxiety disorders (12-month prevalence) by age and gender 
 
Diagnostic group Age 18-34 
M          F 
Age 35-49 
M          F 
Age 50-65 
M          F 
Total 
M          F   
Any anxiety disorder * 7.0        17.0 8.0        15.9 8.4       16.2 7.8        16.3 
Panic disorder (+/- 
agoraphobia) 
1.0          3.4 2.0          3.4 2.1         2.4 1.7         3.0 
Agoraphobia (without 
panic) 
0.9         2.0 1.1          2.9 0.9         4.4 1.0         3.1 
GAD  0.5        1.1 0.9          2.9 1.8         2.2 1.0        2.1     
Social phobia 1.9        3.1 0.7          2.7 1.4        2.2 1.3        2.7 
Specific phobia 4.2      11.9 4.7         9.7 4.6       10.7 4.5      10.8 
OCD 0.4        1.0 1.0         0.9 0.3        0.8 0.6        0.9 
PTSD  0.4        1.6 0.6        1.4 0.4        1.3  0.5         1.5 
 
* without PTSD 
GAD, Generalised Anxiety Disorder; OCD, Obsessive-Compulsive Disorder;  
PTSD, Post-Traumatic Stress Disorder. 
 
Based upon community studies reporting either prevalence estimates for established diagnoses of mental 
disorders (according to DSM-III, DSM-III-R, DSM-IV or ICD-10 criteria) or upon studies employing 
instruments with explicit diagnostic criteria that allow such inferences.  
 
Wittchen HU, Jacobi, F (2005). Size and burden of mental disorder in Europe: A critical review and 
appraisal of studies. Eur J Neuropsychopharmacol 15: 357-376. 
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Table 5.  Summary of potential adverse effects, interactions and other specific problems of named psychotropic drugs used in the treatment of anxiety disorders * 
 
Potential adverse effects Class Examples 
‘Anti-Ch’ Sedation Insomnia ↓ bp Nausea Sexual 
problems 
Weight 
gain 
Specific problems 
64
Inhibition of 
hepatic 
enzymes 
Toxicity  in 
overdose 
Withdrawal 
symptoms 
Selective serotonin 
reuptake inhibitors 
citalopram 
escitalopram 
fluoxetine 
fluvoxamine 
paroxetine 
sertraline 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
+ 
- 
All SSRIs: 
a. can increase 
nervousness in first few 
days of treatment; 
 
b. possible increased 
risk of suicide attempts 
in depressed children 
and adolescents. 
- 
- 
++ 
++ 
++ 
- 
low 
low 
low 
low 
low 
low 
+ 
+ 
? 
+ 
++ 
+ 
Usually only 
transient, when 
present. 
Serotonin-noradrenaline 
reuptake inhibitors 
duloxetine 
venlafaxine 
+ 
+ 
- 
- 
+ 
+ 
- 
- 
+ 
+ (more 
at higher 
doses) 
+ 
+ 
- 
- 
- 
Hypertension. BP and 
ECG monitoring 
suggested. 
- 
- 
? 
medium 
? 
++ 
Selective noradrenaline 
reuptake inhibitors 
maprotiline 
reboxetine 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- + 
+ 
++ 
- 
Seizures 
- 
? 
- 
high 
low 
+ 
? 
Tricyclic 
antidepressants 
amitriptyline 
clomipramine 
desipramine 
imipramine 
++ 
++ 
+ 
++ 
++ 
++ 
+ 
+ 
- 
+ 
+ 
+ 
++ 
++ 
+ 
++ 
- 
+ 
- 
- 
+ 
++ 
+ 
+ 
++ 
+ 
- 
+ 
All TCAs: 
Potentially cardiotoxic 
in therapeutic dosage 
and in overdose. 
++ 
++ 
++ 
++ 
high 
high 
high 
high 
+ 
+ 
+ 
+ 
Monoamine oxidase 
inhibitors 
phenelzine 
moclobemide 
+ 
- 
- 
- 
+ 
+ 
++ 
- 
+ 
+ 
+ 
- 
+ 
- 
Phenelzine: 
Hypertensive crisis with 
sympathomimetics, 
Need to follow 
restricted diet. 
- 
- 
high 
low 
 
++ 
- 
Receptor antagonists mirtazapine + ++ - - - - ++ Blood dyscrasia (as 
common as  with TCAs) 
? low - 
 
 Potential adverse effects Class Examples 
‘Anti-Ch’ Sedation Insomnia ↓ bp Nausea Sexual 
problems 
Weight 
gain 
Specific problems Inhibition of 
hepatic 
enzymes 
Toxicity  in 
overdose 
Withdrawal 
symptoms 
Benzodiazepines 
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alprazolam 
bromazepam 
clonazepam 
diazepam 
lorazepam 
- 
- 
- 
- 
- 
++ 
++ 
++ 
++ 
++ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
All benzodiazepines: 
a. can impair attention 
and memory; 
 
b. tolerance and 
dependence may occur 
Minimal 
effects on 
hepatic 
enzymes; 
pharmaco-
dynamic 
interactions 
with sedative 
drugs. 
Medium. 
Can be 
reversed 
with 
flumazenil. 
++ 
++ 
+ 
+ 
++ 
 
May persist for 
long periods. 
Conventional 
neuroleptics 
haloperidol 
trifluoperazine 
- 
+ 
+ 
++ 
- 
- 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
Risk of development of 
acute and delayed 
movement disorders. 
Many drug 
interactions. 
high 
high 
+ 
+ 
Atypical antipsychotics olanzapine 
quetiapine 
risperidone 
+ 
+ 
+ 
+ 
++ 
+ 
- 
- 
- 
+ 
+ 
+ 
- 
- 
- 
+ 
- 
+ 
++ 
+ 
+ 
All atypicals: 
Risk of hyperglycaemia 
and induction of 
diabetes mellitus. 
+ 
+ 
+ 
low 
low 
low 
? 
? 
? 
Anticonvulsants gabapentin 
pregabalin 
tiagabine 
+ 
- 
- 
+ 
++ 
+ 
- 
- 
- 
? 
- 
- 
+ 
- 
- 
- 
- 
- 
+ 
? 
- 
Potential for the 
development of 
tolerance or dependence 
is not established. 
- ? 
? 
? 
Abrupt 
withdrawal may 
possibly 
precipitate 
seizures.  
Mood stabiliser lithium - - - - + (-) ++ Narrow therapeutic 
window necessitates 
regular blood level 
monitoring. 
- Acute: 
medium; 
Chronic 
intoxication: 
high.  
Abrupt 
withdrawal may 
precipitate 
mania.  
 
 Potential adverse effects Class Examples 
‘Anti-Ch’ Sedation Insomnia ↓ bp Nausea Sexual 
problems 
Weight 
gain 
Specific problems Inhibition of 
hepatic 
enzymes 
Toxicity  in 
overdose 
Withdrawal 
symptoms 
Beta-blockers pindolol 
propranolol 
+ 
- 
Many drug 
interactions. 
medium + 
+ 
- 
- 
+ 
+ 
- + + Avoid in patients with 
asthma, heart failure, 
and peripheral vascular 
disease. 
- + + 
Abrupt 
withdrawal may 
precipitate 
hypertension. 
Antihistamines hydroxyzine + +  
Fast 
tolerance 
- - - ? + Little information on 
benefits and risks.  
? low-medium. ? 
5-HT 1A agonist buspirone + - + - + - - Little information on 
benefits and risks. 
 low - 
 
Annotations 
‘Anti-Ch’, anticholinergic: refers to symptoms commonly caused by muscarinic receptor blockade (including dry mouth, sweating, blurred vision, constipation and urinary retention), although one ore more of these symptoms may 
be caused by other mechanisms and does not necessarily imply that the drug binds to muscarinic receptors; ↓ bp, postural hypotension; ++, relatively common or strong; +, may occur or moderately strong;  
-, absent or weak; ?, unknown or insufficient information.  
 
* Only those psychotropic drugs that are named in the text and currently available for clinical use are considered: naming a drug in this table does not indicate that it has proven 
efficacy or a license for the treatment of anxiety. The side effect profiles given are not comprehensive and provide approximate comparison only. Details of drugs and potential 
cautions and interactions should be looked up in a reference book such as the British National Formulary (2005). 
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Table 6.  
 
Generalised Anxiety Disorder: treatment approaches supported by placebo-controlled studies 
 
  SSRIs TCAs Benzodiazepines Others 
Acute efficacy Escitalopram 
Paroxetine 
Sertraline 
Imipramine Alprazolam 
Diazepam 
Venlafaxine  
CBT 
Buspirone 
Hydroxyzine 
Pregabalin 
Trifluoperazine 
(Abercarnil) 
(Opipramol) 
Long-term efficacy Escitalopram 
Paroxetine 
- - CBT 
Venlafaxine 
Relapse prevention Paroxetine 
Escitalopram 
- - CBT 
Enhances the efficacy of 
psychological treatment 
- - Diazepam - 
After non-response - - - - 
 
Empty cell indicates current absence of published placebo-controlled data. 
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Table 7.  
 
Panic Disorder: treatment approaches supported by placebo-controlled studies 
 
  SSRIs TCAs Benzodiazepines Others 
Acute panic attack - - Alprazolam 
Lorazepam 
- 
Acute efficacy Citalopram 
Escitalopram 
Fluoxetine 
Fluvoxamine 
Paroxetine 
Sertraline 
Clomipramine 
Imipramine 
Alprazolam 
Clonazepam 
Diazepam 
Lorazepam 
CBT 
Phenelzine 
Moclobemide* 
Mirtazapine* 
Venlafaxine 
Reboxetine 
Na valproate 
(Brofaromine) 
(Nefazodone) 
Long-term efficacy Citalopram 
Fluoxetine 
Paroxetine 
Sertraline 
Clomipramine 
Imipramine 
Alprazolam Moclobemide* 
CBT (modest) 
Relapse prevention Fluoxetine 
Paroxetine 
Sertraline 
Imipramine - CBT (modest) 
Enhances the efficacy of 
psychological treatment 
Paroxetine Antidepressants 
(meta-analysis) 
Benzodiazepines 
(meta-analysis) 
Buspirone 
After non-response Paroxetine 
(prior CBT) 
- - Pindolol 
Group-CBT 
* comparator-controlled study only 
 
Empty cell indicates current absence of published placebo-controlled data. 
Table 8. 
 
Social Phobia: treatment approaches supported by placebo-controlled studies 
 
  SSRIs TCAs Benzodiazepines Others 
Acute efficacy Escitalopram - Bromazepam CBT 
Fluoxetine Clonazepam Phenelzine 
Fluvoxamine Moclobemide 
Paroxetine Venlafaxine 
Sertraline Gabapentin 
Pregabalin 
Olanzapine 
(Brofaromine) 
Long-term efficacy Escitalopram - - CBT 
Fluvoxamine Phenelzine 
Paroxetine Moclobemide 
Sertraline Venlafaxine 
Relapse prevention Escitalopram - Clonazepam CBT 
Paroxetine 
Sertraline 
Enhances the efficacy of 
psychological treatment 
Sertraline - - - 
After non-response - - - - 
 
Empty cell indicates current absence of published placebo-controlled data. 
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Table 9. 
 
Post-Traumatic Stress Disorder: treatment approaches supported by placebo-controlled studies 
 
  SSRIs TCAs Benzodiazepines Others 
Prevention of post-
traumatic symptoms? 
- - - Hydrocortisone 
Propranolol 
Trauma-focused 
CBT 
Acute efficacy Fluoxetine Amitriptyline Alprazolam Trauma-focused 
CBT Paroxetine Imipramine 
Sertraline EMDR 
Brofaromine 
Phenelzine 
Lamotrigine 
Mirtazapine 
Venlafaxine 
Long-term efficacy Sertraline - - - 
Relapse prevention Fluoxetine - - CBT? 
Sertraline 
Enhances the efficacy of 
psychological treatment 
- - - - 
After non-response - - - Olanzapine * 
Risperidone * 
 
* placebo-controlled augmentation study 
 
Empty cell indicates current absence of published placebo-controlled data. 
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Table 10. 
 
Obsessive-Compulsive Disorder: treatment approaches supported by placebo-controlled studies 
 
  SSRIs TCAs Benzodiazepines Others 
Acute efficacy Citalopram Clomipramine Clonazepam? CBT 
Fluoxetine Imipramine 
Fluvoxamine
Paroxetine 
Sertraline 
Long-term efficacy Fluoxetine Clomipramine - CBT 
Sertraline 
Relapse prevention Fluoxetine - - - 
Paroxetine 
Sertraline 
Enhances the efficacy of 
psychological treatment 
Fluvoxamine Clomipramine - - 
After non-response - - Clonazepam Another SSRI 
Haloperidol* 
Risperidone* 
Quetiapine* 
Pindolol* 
 
* placebo-controlled augmentation study 
 
Empty cell indicates absence of placebo-controlled data. 
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Figure 1. 
 
Suggested scheme for exploration of a suspected anxiety disorder 
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